The emergence of novel pharmacological treatments, particularly GLP-1 receptor agonists such as semaglutide and dual incretin receptor agonists like tirzepatide, represents one of the most significant developments in obesity management in recent decades [29]. This evidence concerns the gene GLP1R and obesity disorder.